| Title |
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
|
|---|---|
| Published in |
PharmacoEconomics, May 2016
|
| DOI | 10.1007/s40273-016-0412-1 |
| Pubmed ID | |
| Authors |
Jonathan Graham, Doreen McBride, Donald Stull, Anna Halliday, Stamatia Theodora Alexopoulos, Maria-Magdalena Balp, Matthew Griffiths, Ion Agirrezabal, Torsten Zuberbier, Alan Brennan |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| New Zealand | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 43 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 20% |
| Other | 7 | 16% |
| Researcher | 5 | 11% |
| Student > Postgraduate | 4 | 9% |
| Student > Ph. D. Student | 2 | 5% |
| Other | 4 | 9% |
| Unknown | 13 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 34% |
| Biochemistry, Genetics and Molecular Biology | 5 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Economics, Econometrics and Finance | 2 | 5% |
| Computer Science | 1 | 2% |
| Other | 6 | 14% |
| Unknown | 13 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2016.
All research outputs
#16,443,300
of 25,837,817 outputs
Outputs from PharmacoEconomics
#1,594
of 2,008 outputs
Outputs of similar age
#204,796
of 351,487 outputs
Outputs of similar age from PharmacoEconomics
#17
of 22 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,008 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,487 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.